Prevents osteoporosis in postmenopausal women ( 1.1, 1.2 ). Sold as Fosamax, Binosto. Every FDA application for this active ingredient: 3 branded and 17 generic.
As of Nov 16, 2026, FDA lists 20 applications for Alendronate Sodium (sold as Fosamax, Binosto), first approved Sep 29, 1995, with 12 new uses approved and 0 published complete response letters.
| Alendronate Sodium | Part D | $83.4M | +9% | 2,511,440 |
| Fosamax | Part D | $475K | +7% | 445 |
| Binosto | Part D | $457K | 0% | 276 |
| Phase Ib Trial of Injectable RAB001 for Knee OsteoarthritisKnee Osteoarthritis · ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | Phase 1 | Enrolling by invitation | Jun 17, 2026 |
| A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral HeadOsteonecrosis, Osteonecrosis of the Femoral Head · ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. | Phase 2 | Active, not recruiting | Mar 13, 2026 |
| Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III OsteomyelitisOsteomyelitis (Refractory) · Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Not yet recruiting | Feb 27, 2026 |
| Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing ChemoradiationCervix Cancer · Dr. Itay GoorAryeh | Phase 1 / Phase 2 | Not yet recruiting | Nov 24, 2025 |
| Small Trial of Alendronate Impact on the Reservoir of HIVHIV · National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Recruiting | Oct 15, 2025 |
| A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without FracturesOsteoporosis in Post-menopausal Women · Odense University Hospital | Phase 4 | Recruiting | Mar 7, 2025 |
| Clinical Efficacy of 1% Metformin and Alendronate Gel in Adjunct to Fibrin in Chronic PeriodontitisAlveolar Bone Loss Associated Chronic Periodontitis · Bahria University | Phase 4 | Active, not recruiting | Mar 4, 2025 |
| Precision Medicine Approach for Osteoporosis - Follow Up StudyOsteoporosis · Paul F Netzel | Phase 4 | Enrolling by invitation | Feb 20, 2024 |
| Sep 29, 1995 | FosamaxNDA 20560 · New molecular entity | Organon | 53 | Marketed |
| Sep 17, 2003 | FosamaxNDA 21575 · New dosage form | Merck | 20 | Discontinued |
| Feb 6, 2008 | Alendronate SodiumANDA 75710 | Impax Labs Inc | 11 | Discontinued |
| Feb 6, 2008 | Alendronate SodiumANDA 76184 | Teva Pharms | 5 | Discontinued |
| Aug 4, 2008 | Alendronate SodiumANDA 76584 | Rising | 10 | Discontinued |
| Aug 4, 2008 | Alendronate SodiumANDA 76768 | Cipla | 4 | Marketed |
| Aug 4, 2008 | Alendronate SodiumANDA 76984 | Watson Labs | 6 | Marketed |
| Aug 4, 2008 | Alendronate SodiumANDA 77982 | Apotex | 8 | Discontinued |
| Aug 4, 2008 | Alendronate SodiumANDA 78638 | Mylan | 0 | Discontinued |
| Aug 4, 2008 | Alendronate SodiumANDA 79049 | Chartwell Rx | 4 | Discontinued |
| Aug 4, 2008 | Alendronate SodiumANDA 90124 | Aurobindo Pharma | 14 | Marketed |
| Sep 10, 2008 | Alendronate SodiumANDA 90022 | Sun Pharm | 9 | Marketed |
| Apr 22, 2009 | Alendronate SodiumANDA 75871 | Chartwell Rx | 3 | Discontinued |
| Sep 24, 2009 | Alendronate SodiumANDA 90258 | Hangzhou Binjiang | 4 | Marketed |
| Feb 18, 2010 | Alendronate SodiumANDA 90557 | Jubilant Cadista | 5 | Discontinued |
| Mar 12, 2012 | BinostoNDA 202344 · New dosage form | Radius | 12 | Discontinued |
| Feb 25, 2013 | Alendronate SodiumANDA 90520 | Hikma | 5 | Marketed |
| May 11, 2023 | Alendronate SodiumANDA 214512 | Novitium Pharma | 1 | Marketed |
| Jun 4, 2024 | Alendronate SodiumANDA 206387 | Ipca Labs Ltd | 1 | Marketed |
| Sep 2, 2026 | Alendronate SodiumANDA 214523 | Precision Dose Inc | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA